What Did the Research Discover? Researchers conducted a phase 3 clinical trial to evaluate whether adding nivolumab, an immune therapy, to the standard chemotherapy drugs gemcitabine and cisplatin would improve survival for patients with advanced urothelial carcinoma (a type of bladder cancer). The study included 608 patients with unresectable or metastatic...
